Post-grant proceedings: shaping the biotech landscape

In March 2010, the Biologics Price Competition and Innovation Act (BPCIA) created an abbreviated pathway for licensing biosimilars and a 12-year exclusivity period for first licensed biologics. Shortly after, the America Invents Act (AIA) provided multiple changes to the patent system and established a variety of post-grant proceedings. Notably, the AIA established post-grant review (PGR) proceedings and inter partes review (IPR) proceedings.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Masimo convinces judge that Apple took secrets—but it’s not enough

19 March 2026 Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.

Americas

J&J unit targets former employee over alleged mass data theft

17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.

Americas

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.

More features

Masimo convinces judge that Apple took secrets—but it’s not enough

Sandoz strikes fresh biosimilar deal with South Korean biotech

J&J unit targets former employee over alleged mass data theft

INTA: ‘New normal’ for in-house counsel as budgets fall

Mylan withdraws defence claims against Novo in Wegovy dispute

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Astellas blocks generic version of key urology drug until 2030

Orrick adds specialist licensing partner in Silicon Valley

Post-grant proceedings: shaping the biotech landscape

More on this story

Editor's picks

Editor's picks

More features